

# The Meeting of the Bangladesh, Bhutan, India, Nepal, Sri Lanka (BBINS) Malaria Drug Resistance Monitoring Network

A Report

New Delhi, India, 15–16 October 2019



REGIONAL OFFICE FOR

**World Health  
Organization**

**South-East Asia**



The Meeting of the Bangladesh, Bhutan,  
India, Nepal, Sri Lanka (BBINS)  
Malaria Drug Resistance Monitoring Network

*A Report*

*New Delhi, India, 15–16 October 2019*

The Meeting of the Bangladesh, Bhutan, India, Nepal, Sri Lanka (BBINS) Malaria Drug Resistance Monitoring Network  
SEA-MAL-283

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO license (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this license, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the license shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. The Meeting of the Bangladesh, Bhutan, India, Nepal, Sri Lanka (BBINS) Malaria Drug Resistance Monitoring Network, Regional Office for South-East Asia; 2018. License: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

## Contents

	<i>Page</i>
Abbreviations.....	v
Summary.....	vii
1. Background.....	1
2. Objectives of the meeting were:.....	1
3. Proceedings.....	2
4. Session 1: Technical updates.....	2
4.1 Updates on antimalarial drug resistance, artemisinin resistance .....	2
4.2 Regional updates and review of TES studies in BBINS .....	3
4.3 Different drug efficacy surveillance systems: routine TES, integrated drug efficacy surveillance (iDES) in the context of elimination, and importation .....	4
4.4 A brief overview of the TES protocol template .....	5
5. Session 2: Country Presentations on TES .....	6
5.1 Bangladesh (Dr Nazrul Islam, National Malaria Elimination and ATD Control Program).....	6
5.2 India (Dr Avdhesh Kumar, National Director, NVBDCP) .....	7
5.3 India (Dr Praveen K. Bharti, Scientist-E, NIRTH and Dr Kuldeep Singh, Scientist-B & Officer-in-charge, ICMR-NIMR) .....	8
6. Session 3. Country presentations on iDES.....	11
6.1 Bhutan (Mr Singay Dukpa, Laboratory Officer, VDCP) .....	11
6.2 Maldives (Aishath Jaleela, Director, Pharmaceuticals, Food and Drug Authority) ...	11
6.3 Sri Lanka (Dr Muzrif Munas, CCP, Anti-Malaria Campaign and Dr Priyani Dharmawardena, Regional Malaria Officer, Ministry of Health) .....	12
7. Session 4: Updates on quality control and molecular markers .....	13
7.1 Quality control in TES and iDES: implementation challenges (Dr Maria Dorina Bustos) .....	13
7.2 Phenotypic and genotypic monitoring of resistance: GMS experience (Dr Benoit Witkowski, Pasteur Institute, Cambodia) .....	14
7.3 Role of the Malaria Elimination Research Alliance and ICMR in supporting the TES network in the SEA Region (Dr Manju Rahi, ICMR) .....	15
8. Session 5: Harmonization of treatment regimen and evidence to policy (Panel discussion chaired by Dr Kamini Mendis) .....	16
9. Session 6: Presentation of country plans and budget: TES + MM and iDES .....	16

10. Session 7: Conclusion and recommendations .....	18
10.1 Conclusions of the Meeting: .....	18
10.2 Recommendations made to the countries of the BBINS Network.....	18
10.3 Recommendations made to WHO .....	19

## Annexes

1. Agenda .....	20
2. List of participants .....	22

## Abbreviations

ACD	active case detection
ACPR	adequate clinical and parasitological response
ACT	artemisinin-based combination therapy
AL	artemether-lumefantrine
API	annual parasite incidence
AS	artesunate
BBINS	Bangladesh, Bhutan, India, Nepal, Sri Lanka
CDS	Communicable Diseases Department
CQ	chloroquine
DHA	dihydroartemisinin
ECA	external competency assessment
ERC	Ethics Review Committee
ETF	early treatment failure
GMP	Global Malaria Programme
GMS	Greater Mekong Subregion
GTS	Global Technical Strategy
ICF	informed consent forms
iDES	integrated Drug Efficacy Surveillance
K13	Kelch 13
LCF	late clinical failure
LPF	late parasitological failure
MQ	mefloquine
NMCP	National Malaria Control Programme
NSP	National Strategic Plan
NTG	National Treatment Guidelines
NVBDCP	National Vector Borne Disease Control Programme
PCD	passive case detection
PCR	polymerase chain reaction
PIP	piperaquine
PQ	primaquine
QA	quality assurance
RDT	rapid diagnostic test
SEARO	(WHO) Regional Office for South-East Asia
SP	sulfadoxine-pyrimethamine
TES	therapeutic efficacy studies
WHO	World Health Organization

预览已结束，完整报告链接和二

<https://www.yunbaogao.cn/report/index/report?rep>